CO
COGT.US Cogent Biosciences Inc
- Market cap
- USD 4.97B
- P/E
- -
- P/B
- 11.24x
- ROE
- -78.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is COGT.US undervalued?
Graham numberThe Graham number of Cogent Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cogent Biosciences Inc fundamental analysis
No fundamental analysis for Cogent Biosciences Inc yet.
Cogent Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced ga…
Full company profileCogent Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cogent Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.36M | 8.36M | 9.73M | 22.5M | 7.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 6.36M | 8.36M | 9.73M | 22.5M | -17.9M | -147K | -5.88M | -3.59M | -4.40M | -4.62M | - |
| Operating Income | -19.1M | -26.2M | -36.0M | -32.2M | -82.2M | -75.6M | -148M | -208M | -276M | -333M | -431M |
| EBITDA | -18.2M | -25.0M | -34.7M | -30.9M | -34.6M | -72.1M | -142M | -189M | -252M | -321M | -399M |
| Net Income | -18.1M | -25.5M | -34.5M | -30.3M | -74.8M | -72.3M | -133M | -192M | -256M | -329M | -407M |
| EPS | -2.45 | -3.45 | -5.55 | -3.97 | -6.75 | -1.87 | -2.26 | -2.42 | -2.32 | -2.04 | -2.35 |
| Balance Sheet | |||||||||||
| Total Assets | 75.6M | 49.1M | 85.9M | 49.4M | 251M | 232M | 301M | 313M | 328M | 938M | 832M |
| Total Liabilities | 23.2M | 20.8M | 25.7M | 17.7M | 16.2M | 17.9M | 45.1M | 55.6M | 71.6M | 301M | 316M |
| Shareholders' Equity | 52.4M | 28.3M | 60.2M | 31.8M | 235M | 214M | 256M | 258M | 256M | 636M | 516M |
| Cash & Short-term Investments | 68.5M | 41.0M | 78.6M | 37.4M | 242M | 220M | 259M | 266M | 287M | 901M | 791M |
| Total Debt | - | - | - | 6.03M | 5.21M | 3.16M | 19.6M | 18.9M | 17.5M | 253M | 244M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.6M | -25.8M | -32.5M | -41.5M | -35.9M | -58.8M | -119M | -154M | -208M | -264M | -327M |
| Capital Expenditure | 3.31M | 912K | 549K | 33.0K | 320K | 1.72M | 6.86M | 2.80M | 573K | 1.55M | 1.24M |
| Free Cash Flow | -21.9M | -26.7M | -33.0M | -41.5M | -35.9M | -60.5M | -126M | -156M | -208M | -266M | -328M |
| Ratios | |||||||||||
| ROE | -34.6% | -90.1% | -57.3% | -95.3% | -31.9% | -33.7% | -51.9% | -74.6% | -99.8% | -51.7% | -78.8% |
| ROA | -24.0% | -51.9% | -40.2% | -61.3% | -29.8% | -31.1% | -44.1% | -61.4% | -78.0% | -35.1% | -48.9% |
| Net Profit Margin | -285.2% | -304.9% | -354.8% | -134.6% | -950.4% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.19x | 0.02x | 0.01x | 0.08x | 0.07x | 0.07x | 0.40x | 0.47x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cogent Biosciences Inc dividends
Cogent Biosciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Nov 9, 2020.
Who owns Cogent Biosciences Inc
- Insiders 1.38%
- Institutions 98.62%
- Public & others 0.00%
- Shares outstanding 174M
- Free float 173M
Top funds holding COGT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.18M | 2.99% | +0.30% | Sep 2026 |
| iShares Russell 2000 ETF | 4.23M | 2.44% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 4.18M | 2.41% | +2.68% | Oct 2026 |
| Vanguard Small Cap Index | 3.71M | 2.14% | -0.78% | Sep 2026 |
| Polar Capital Biotech S Inc | 3.30M | 1.90% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 2.51M | 1.45% | 0.00% | Aug 2026 |
| Vanguard MStar Small Cap Value Index | 2.41M | 1.39% | +1.80% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 2.14M | 1.24% | +35.79% | Sep 2026 |
| Fidelity OTC | 1.87M | 1.08% | 0.00% | Aug 2026 |
| Fidelity Select Health Care | 1.85M | 1.07% | 0.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 1.83M | 1.06% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.82M | 1.05% | +0.15% | Aug 2026 |
| Lord Abbett Growth Leaders I | 1.71M | 0.98% | -1.33% | Aug 2026 |
| Fidelity Select Biotechnology | 1.60M | 0.92% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.57M | 0.90% | -0.38% | Oct 2026 |
| Pictet-Biotech P USD | 1.53M | 0.88% | +14.34% | Jul 2026 |
| Fidelity Stock Selector Small Cap | 1.36M | 0.78% | 0.00% | Aug 2026 |
| Invesco Discovery A | 1.26M | 0.72% | +10.04% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 1.25M | 0.72% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 1.21M | 0.70% | -0.49% | Oct 2026 |
Top institutions holding COGT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 25.7M | 14.80% | +11.06% | Jun 2026 |
| BlackRock Inc | 17.4M | 10.00% | +8.15% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 8.07M | 4.65% | +10.08% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.41M | 4.27% | +7.50% | Jun 2026 |
| State Street Corp | 6.96M | 4.01% | +22.98% | Jun 2026 |
| Jupiter Topco LLC | 6.62M | 3.82% | 0.00% | Jun 2026 |
| Fairmount Funds Management LLC | 5.50M | 3.17% | 0.00% | Jun 2026 |
| Deerfield Management Co | 5.01M | 2.88% | -44.65% | Jun 2026 |
| TCG Crossover Management, LLC | 4.85M | 2.80% | -1.87% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 4.65M | 2.68% | +44.82% | Jun 2026 |
| Geode Capital Management, LLC | 4.51M | 2.60% | +21.88% | Jun 2026 |
| Wellington Management Company LLP | 4.34M | 2.50% | +21.39% | Jun 2026 |
| Kynam Capital Management, LP | 3.67M | 2.11% | -9.17% | Jun 2026 |
| Lord, Abbett & Co LLC | 3.43M | 1.98% | +7.85% | Jun 2026 |
| Polar Capital Holdings PLC | 3.23M | 1.86% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 3.05M | 1.76% | +5.61% | Jun 2026 |
| Assenagon Asset Management SA | 2.88M | 1.66% | +875.31% | Jun 2026 |
| Amvescap Plc. | 2.61M | 1.50% | +7.39% | Jun 2026 |
| Woodline Partners LP | 2.60M | 1.50% | +72.45% | Jun 2026 |
| Pictet Asset Manangement SA | 2.39M | 1.38% | +33.06% | Jun 2026 |
Cogent Biosciences Inc company profile
- Company name
- Cogent Biosciences Inc
- Ticker
- COGT.US
- Exchange
- USA Stocks
- Listed since
- Mar 29, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 258
- Fiscal year end
- December
- Address
- 180 Third Avenue, Waltham, MA, United States, 02451
- Phone
- (617) 945-5576
- Website
- cogentbio.com
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Cogent Biosciences Inc management
10- Mr. Andrew R. Robbins M.B.A.President, CEO & Director · born 1976
- Mr. John L. Green C.A., CPACFO & Principal Accounting Officer · born 1980
- Dr. John Edward Robinson Ph.D.Chief Scientific Officer · born 1974
- Dr. Jessica Sachs M.D.Chief Medical Officer · born 1975
- Mr. Cole PinnowChief Commercial Officer · born 1975
- Mr. Brad BarnettChief Technology Officer
- Ms. Christi WaarichSenior Director of Investor Relations
- Mr. Evan D. Kearns J.D.Chief Legal Officer & Corporate Secretary · born 1980
- Mr. Abb HaydenSenior Vice President of Sales
- Ms. Erin SchellhammerChief People Officer